Ropes & Gray advised oncology company Revolution Medicines in a multi-part collaboration with BeOne Medicines announced on August 10.
The deal includes a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS (ON) inhibitors for RAS-addicted cancers, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets.
Revolution Medicines is eligible to receive development and sales milestone payments and tiered royalties on net sales in the partnered region. Revolution Medicines retains development and commercial rights to all its assets outside of the licensed territory, including Japan and South Korea.
The Ropes & Gray team was led by life sciences licensing partner Hannah England and associates Shuang Ci and Nicole Rohr and included life sciences partner Katherine Wang, health care partner David Peloquin, tax partner David Saltzman, data privacy & cybersecurity counsel Edward Machin, IP transactions associates Ian Nilsen and Oceania Eshraghi and life sciences regulatory & compliance associate Becca Williams.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.